Filing Flows › Iradimed (IRMD) › Guidance & outlook
Iradimed (IRMD) guidance and outlook
Iradimed (IRMD) lowered its guidance on Oct 30, 2026: Revenue $25.0M–$26.5M for Q4 2026; EPS $0.53–$0.57 for Q4 2026; EPS $0.57–$0.61 for Q4 2026; Revenue $91.6M–$93.1M for FY2026. Iradimed's 10-Q filed Oct 30, 2026 makes 7 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | Q4 2026 | $25.0M–$26.5M | new |
| EPS | Q4 2026 | $0.53–$0.57 | new |
| EPS | Q4 2026 | $0.57–$0.61 | new |
| Revenue | FY2026 | $91.6M–$93.1M | lowered |
| EPS | FY2026 | $1.90–$1.94 | lowered |
| EPS | FY2026 | $2.07–$2.11 | lowered |
From the earnings release filed Oct 30, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Oct 30, 2026
- For the fiscal year 2026, we expect higher revenue when compared to the fiscal year 2025 primarily due to higher sales of our medical devices and products, related accessories, disposables, and services.
- We also expect higher operating expenses compared to the fiscal year 2025 primarily due to higher sales and marketing, regulatory, and general and administrative expenses.
- Management’s Discussion and Analysis of Financial Condition and Results of Operations,” our business in fiscal year 2026 has been impacted, and we believe will continue to be impacted, by the recent developments and trends described in the 2025 Annual Report and in this Quarterly Report.
- The Company will continue to actively assess potential risks and implement mitigation strategies, where appropriate, to address any emerging impacts.
- The Company has evaluated the impact of the OBBBA on its financial statements and does not expect the legislation to result in a material change to its annual effective tax rate.
- We do not anticipate requiring additional capital; however, if required or desirable, we may seek to obtain a credit facility, raise debt, or issue additional equity in private or public markets.
- Various economic conditions (including persistent inflationary pressures, elevated or volatile interest rate levels, and the imposition of, expansion of, or changes in tariffs or other trade restrictions) may disrupt capital markets at any time, which could reduce our ability to access capital and negatively affect our liquidity in the future.
Iradimed's latest quarter
Iradimed, Q3 2026: revenue $24.2M (+14% year over year), operating margin 33.6%, net earnings $6.5M, operating cash flow $7.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Iradimed raise or lower its guidance?
Iradimed (IRMD) lowered its guidance on Oct 30, 2026: Revenue $25.0M–$26.5M for Q4 2026; EPS $0.53–$0.57 for Q4 2026; EPS $0.57–$0.61 for Q4 2026; Revenue $91.6M–$93.1M for FY2026.
What does Iradimed expect?
For the fiscal year 2026, we expect higher revenue when compared to the fiscal year 2025 primarily due to higher sales of our medical devices and products, related accessories, disposables, and services. We also expect higher operating expenses compared to the fiscal year 2025 primarily due to higher sales and marketing, regulatory, and general and administrative expenses. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” our business in fiscal year 2026 has been impacted, and we believe will continue to be impacted, by the recent developments and trends d
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.